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Abstract 
Excessive bleeding after cardiac surgery is a serious complication that is associated 
with increased morbidity and mortality. The bleeding is multifactorial and influ-
enced by both surgical factors and impaired haemostasis. It is important to identify 
patients with increased risk of bleeding before the operation so countermeasures 
can be initiated. A large proportion of cardiac surgical patients receive blood trans-
fusions during and after surgery. Transfusion therapy can save lives, but is also 
associated with increased risk of morbidity and mortality, so unnecessary transfu-
sions should be avoided. There is little knowledge about when and on what indica-
tion blood transfusions are administered, and how well treating physicians follow 
current guidelines. 
Aims: One aim was to examine the relationship between preoperative levels of 
fibrinogen and other coagulation factors, and their relationship to postoperative 
bleeding and blood transfusion. Another was to assess the effects of a structured 
blood conservation programme, with the objective of reducing the administration of 
blood transfusions in cardiac surgical patients. A third aim was to study the preva-
lence, volumes and indications for red blood cell transfusions in cardiac surgery 
patients. The final aim was to examine adherence to institutional transfusion guide-
lines. 
 
Materials and methods: The first study (Paper I) involved 170 patients undergoing 
coronary artery bypass grafting (CABG). Data on each patient´s preoperative fi-
brinogen plasma concentration and other haemostatic tests, and postoperative bleed-
ing and transfusion requirements, were collected. In Paper II, the study concerned 
57 CABG patients. Plasma activity of coagulation factors involved in plasma coag-
ulation was measured before and after surgery and related to haemodilution and 
postoperative blood loss. In Paper III, the study involved all 2162 patients who 
underwent cardiac surgery at our institution during a 24-month period. Transfusion 
requirements and transfusion-associated costs before and after introduction of a 
blood conservation programme were compared. In the study described in Paper IV, 
timing and indications for red blood cell transfusion in 1034 cardiac surgery pa-
tients were investigated and the adherence to institutional guidelines was assessed.  
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Results: Paper I demonstrated that preoperative plasma levels of fibrinogen corre-
lates significantly to postoperative blood loss. Preoperative fibrinogen level was 
also an independent predictor of red blood cell transfusion, together with female 
gender and long operation time. Paper II demonstrated a marked disparity of clot-
ting factor activity after cardiac surgery. Only plasma concentration of fibrinogen 
and coagulation factor XIII activity correlated to postoperative bleeding. Paper III 
showed that the introduction of a simple structured multifactorial blood conserva-
tion programme significantly reduces blood transfusions to cardiac surgery patients, 
and reduces transfusion-associated costs without compromising medical safety. The 
result persists for at least three years after the implementation of the programme. 
Paper IV demonstrated that red blood cells are often transfused for other reasons 
than anaemia. The adherence to institutional transfusion guidelines was low. 
Conclusions: Pre- and postoperative fibrinogen concentration and factor XIII activi-
ty predict postoperative bleeding volume after CABG and may be used to identify 
patients with increased risk of bleeding. The introduction of a structured blood 
conservation programme is safe and reduces the use of blood products in cardiac 
surgery. The adherence to transfusion guidelines among treating physicians is low.   
Keywords: cardiac surgery, bleeding, fibrinogen, blood transfusion, transfusion 
guidelines, adherence  
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Sammanfattning på svenska 
Bakgrund: Massiv blödning efter hjärtkirurgi är en allvarlig komplikation som är 
förknippad med ökad sjuklighet och dödlighet. Blödningen kan orsakas av många 
faktorer, bl. a av försämrad koagulationsförmåga till följd av ingreppet. Det är av 
stort värde att kunna identifiera patienter med ökad risk för blödning, då motåtgär-
der kan sättas in i samband med operationen. En stor andel hjärtkirurgiska patienter 
erhåller blodtransfusioner under och efter operationen. Transfusionsbehandling kan 
rädda liv, men kan också leda till ökad risk för sjuklighet och död efter hjärtkirurgi. 
Därför bör onödiga transfusioner undvikas. Det finns lite kunskap om när och på 
vilken indikation blodtransfusioner ges, och hur väl behandlande läkare följer rå-
dande riktlinjer. 
Frågeställning: I avhandlingen undersöktes preoperativa plasmanivåer av fibrino-
gen och andra koagulationsfaktorer, och deras relation till postoperativ blödning 
och blodtransfusion. Vidare analyserades effekten av ett aktivt åtgärdsprogram, vars 
syfte var att minska andelen blodtransfusioner till hjärtkirurgiska patienter. Utöver 
det studerades förekomst av blodtransfusioner, indikationer för transfusioner samt i 
vilken utsträckning klinikens transfusionsriktlinjer följdes.  
Metodik: I det första delarbetet studerades 170 patienter som genomgått kranskärls-
kirurgi. Data rörande plasmakoncentration av fibrinogen och andra blodprover 
viktiga för hemostas, samt postoperativ blödning och blodtransfusionsbehov inhäm-
tades. I delarbete II studerades 57 patienter som genomgått kranskärlskirurgi. 
Plasmaaktivitet för koagulationsfaktorer mättes före och efter kirurgi och relatera-
des till postoperativ blodförlust och den spädning av blodet som uppkommer i sam-
band med användandet av hjärt- lungmaskin. I delarbete III studerades alla 2162 
patienter som under en tvåårsperiod genomgått hjärtkirurgi på Thoraxkirurgiska 
kliniken, Sahlgrenska Universitetssjukhuset. Blodtransfusionsbehov och transfus-
ionsrelaterade kostnader registrerades före och efter att ett blodbesparingsprogram 
infördes. I delarbete IV undersöktes tidpunkten och indikationerna för transfusion 
av röda blodkroppar hos 1034 hjärtkirurgiska patienter. Information om hur väl 
behandlande läkare följde klinikens riktlinjer inhämtades.  
Resultat: I delarbete I visades att preoperativa fibrinogennivåer korrelerar till 
postoperativ blödning. Preoperativa fibrinogennivåer, kvinnligt kön och lång oper-
ationstid var också oberoende prediktorer för transfusion av röda blodkroppar. I 
delarbete II visades att det föreligger en markant spridning av koagulationsfak-
toraktiviteten efter hjärtkirurgi. Bara plasmakoncentrationen av fibrinogen och 
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faktor XIII-aktiviteten korrelerade till postoperativ blödning. I delarbete III visa-
des att introduktionen av ett enkelt strukturerat blodbespringsprogram minskar 
blodtransfusioner till hjärtkirurgiska patienter utan att äventyra den medicinska 
säkerheten, samtidigt som de transfusionsrelaterade kostnaderna minskar. I delar-
bete IV visades att behandlande läkare följde klinikens riktlinjer för blodtransfus-
ioner i anmärkningsvärd låg utsträckning.  
Slutsatser: Pre- och postoperativa fibrinogennivåer och faktor XIII-aktivitet predik-
terar postoperativ blödningsvolym efter kranskärlskirurgi, och skulle därför kunna 
användas för att identifiera patienter med ökad risk för blödning. Införandet av ett 
strukturerat blodbesparingsprogram är medicinskt säkert och minskar användandet 
av blodprodukter inom hjärtkirurgi. Behandlande läkare följer klinikens riktlinjer 
för blodtransfusioner i låg utsträckning. 
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Abbreviations 
ACT Activated clotting time 
ADP  Adenosine diphosphate 
ANOVA Analysis of variance 
APTT Activated partial thromboplastin time 
AT Antithrombin 
CABG Coronary artery bypass grafting 
CI Confidence interval 
CPB Cardiopulmonary bypass 
ECC Extracorporeal circulation 
EVF Erythrocyte volume fraction 
Hb Haemoglobin 
HCT Haematocrit 
ICU Intensive care unit 
LMWH Low molecular weight heparin 
NOAC Non-vitamin K oral anticoagulants 
OR Odds ratio 
PCI Percutaneous coronary intervention 
PFT Platelet function test 
PLG Plasminogen 
RBC Red blood cells 
SD Standard deviation 
SSRI Selective serotonin reuptake inhibitors 
TEM Thromboelastometry 
TF Tissue factor 
tPA Tissue plasminogen activator 
uPA Urokinase plasminogen activator 
vWF von Willebrand factor 
WHO World Health Organization 
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Introduction 
In his textbook ‘The surgery of the chest’ from 1896, Sir Stephen Paget, a British 
surgeon, remarked that ”Surgery of the heart has probably reached the limit set by 
Nature to all surgery: no new method and no new discovery can overcome the 
natural difficulties that attend a wound to the heart.” (1). Ten years later, the 
German surgeon Ludwig Rehn repaired a right ventricle stab wound (2). This is 
commonly referred to as the first successful heart operation and the birth of cardi-
ac surgery. Today cardiac surgery is the standard treatment in many congenital 
and acquired heart diseases. 
 
In Sweden the number of procedures in cardiac surgery has decreased steadily 
since the turn of the millennium. The main reason is the development of percuta-
neous coronary interventions (PCI), leading to a decrease in coronary artery by-
pass grafting surgery (CABG) procedures. In 2000, more than 9000 cardiac surgi-
cal procedures were performed in Sweden, with a 30-day mortality of 3.6% (3). In 
2013, only 5685 procedures were reported. The overall 30-day mortality is still 
low (2.9%), although patients now are older and more critically diseased than 
previously (4). 
 
Even though cardiac surgery is constantly developing, there are still risks of se-
vere complications such as stroke (5), infections (6), myocardial infarction and 
heart failure (7), renal insufficiency (8), and pulmonary dysfunction (9). Severe 
postoperative bleeding is a serious complication after cardiac surgery, resulting in 
increased morbidity and mortality (10, 11). This thesis considers some clinical 
aspects of bleeding and transfusion in cardiac surgery. More specifically, the im-
portance of different coagulation factors for postoperative bleeding and transfu-
sions was determined, the effects of a blood conservation programme on utilisa-
tion and costs of blood products were evaluated, and indications for blood transfu-
sions and adherence to transfusion guidelines were assessed.  
Cardiac surgery and bleeding 
Bleeding after cardiac surgery is multifactorial, and can be caused by both im-
paired haemostasis and surgical factors (10). Impaired haemostasis may be related 
to coagulopathy caused by the exposure of blood to artificial surfaces, haemodilu-
tion, platelet dysfunction, enhanced fibrinolysis and the surgical trauma (12). 
Antiplatelet drugs are widely used in the treatment of patients with coronary artery 
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disease, and preoperative medication with platelet inhibitors (clopidogrel, ticagre-
lor, prasugrel and glycoprotein IIb/IIIa blockers) and medications affecting the 
coagulation cascade (low molecular heparin, warfarin and non-vitamin K oral 
anticoagulants [NOACs]) may contribute to increased postoperative bleeding (13-
15). 
 
Bleeding is one of the most common and serious complications after cardiac sur-
gery. The average cardiac surgery patient bleeds 500-1200 ml postoperatively, and 
about 5% of all cardiac surgery patients are re-explored due to excessive bleeding 
or tamponade (11). Re-exploration for bleeding is defined as a necessary re-
opening of the surgical wound, to achieve haemostasis in patients with sudden 
massive bleeding or persisting bleeding that cannot be explained by coagulation 
dysfunction. There is convincing evidence that re-exploration is an independent 
risk factor for morbidity and mortality in cardiac surgery (10, 16, 17).  
Identifying patients at risk of excessive postoperative bleeding would offer the 
possibility to optimise perioperative management. If patients with increased risk 
were identified, countermeasures could be initiated. An impaired haemostasis 
status can be treated with pro-coagulant substances or blood products, but the 
methods may be associated with increased risk for thromboembolic complications. 
Change in surgical approach or postponing the operation are other possible pre-
ventive actions. 
Prior to cardiac surgery there is a widespread use of laboratory tests. Routine 
screening tests such as activated thromboplastin time (aPTT), prothrombin time 
(PT) and platelet count, have no or limited ability to identify patients with in-
creased bleeding risk (18-20). When the work with this thesis began there was no 
explicit laboratory test for predicting bleeding after cardiac surgery. 
Haemostasis 
Upon vascular damage there is an immediate reflex that promotes vasocon-
striction, diminishing blood loss. The first step in haemostasis is when platelets 
adhere to the exposed subendothelium. Platelets undergo change in shape and 
degranulation and release cytoplasmic granules containing serotonin, ADP and 
thromboxane A2 (21). The ADP attracts more platelets and thromboxane A2 pro-
motes platelet aggregation, degranulation and vasoconstriction. ADP and throm-
boxane A2 promote additional platelet aggregation and consequently more ADP 
and thromboxane A2 (22). This promotes the formation of a platelet plug, the 
second step in haemostasis, followed by plasma coagulation, the final haemostatic 
mechanism. 
  15 
Coagulation 
The coagulation cascade has two possible initiation pathways leading to thrombin 
generation. In the extrinsic or tissue factor system, (the physiological one), suben-
dothelial structures and monocytes expose tissue factor (TF) upon vascular dam-
age. Circulating FVIIa binds to TF, and this complex activates FX and additional 
FVII and FIX. On the surface of activated platelets, FXa together with FVa acti-
vate prothrombin into thrombin. Thrombin is central in the coagulation and is 
responsible for several critical reactions, by cleaving fibrinogen into fibrin, acti-
vating platelets, playing an important role in positive feedback activation of coag-
ulation, and being critical for clot formation (23, 24). The intrinsic or contact 
system pathway is initiated by the activation of contact system and FXII on for-
eign surfaces. Activation of FXII is followed by activation of FXI and FIX. The 
intrinsic and extrinsic pathways converge into the final common pathway at the 
level of FX activation (25). FXIII, when activated by thrombin, builds cross-links 
between the fibrin strands to form a stable clot. 
 
 
Figure 1. The coagulation cascade. Reproduced with permission of 
themedicalbiochemistrypage, LLC. 
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Fibrinolysis 
To avoid widespread thrombosis, the fibrin clot is degraded soon after formation, 
a mechanism called fibrinolysis. Under physiological conditions, coagulation and 
fibrinolysis are in perfect balance. Plasmin is the major fibrinolytic enzyme. Its 
precursor, plasminogen (PLG) is a circulating plasma protein and can be convert-
ed into plasmin by tissue plasminogen activator (tPA) and urokinase plasminogen 
activator (uPA) (26). Fibrin regulates its own degradation by binding PLG and 
tPA on its surface. Once formed, plasmin cleaves the fibrin strands, generating 
degradation products cleared by other proteases and the liver and kidneys.    
Fibrinogen 
Fibrinogen, or coagulation factor I, is a key protein in achieving and maintaining 
haemostasis. It is a soluble plasma glycoprotein synthesised and secreted by the 
liver, with a molecular weight of 340 kDa. In a healthy individual, plasma concen-
tration of fibrinogen ranges from 2.0 to 4.5 g/L (27). Daily turnover of fibrinogen 
is 2-5 g and half-life in plasma is 5 days. After bleeding, baseline level of fibrino-
gen is restored within 12 hours (28-30). 
Fibrinogen is a dimeric molecule with each part consisting of three chains linked 
by disulphide bridges. Thrombin cleaves the chains to release the fibrinopeptides 
from the aminoterminal ends. After fibrinopeptide release, the fibrin monomers 
undergo polymerisation, and are stabilised by FXIII to form an insoluble fibrin 
clot. Fibrinogen also plays an important role in platelet aggregation by cross-
linking activated platelets. Activated platelets express on their surface the activat-
ed platelet membrane glycoprotein receptor GP IIb/IIIa, which binds fibrinogen. 
There are studies indicating that low plasma fibrinogen levels are associated with 
an increased risk of bleeding (31). 
Physiological as well as pathological and lifestyle factors influence fibrinogen 
concentration. Elevated levels due to ageing, in female gender, in pregnant and 
menopausal women (32), and during treatment with oral contraceptives (33) have 
been observed. Fibrinogen is an acute phase reactant that increases considerably in 
response to pro-inflammatory agents (34). Fibrinogen concentration is a strong 
independent risk factor for cardiovascular disorders, and associations between 
increased fibrinogen levels and risk for coronary heart disease, stroke, peripheral 
arterial disease and total mortality have been shown (35, 36). 
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Figure 2. Schematic representation of the fibrinogen molecule. 
 
In massive bleeding, fibrinogen concentration may be more important than previ-
ously assumed. An inverse correlation between plasma fibrinogen concentration 
and perioperative bleeding in cardiac and scoliosis surgical patients has been 
demonstrated (37-40). A human fibrinogen concentrate has been on the market 
since 1986. Initially the product was approved for treatment and prophylaxis of 
haemorrhagic diatheses in congenital and acquired fibrinogen deficiency, but 
recently the same product has been made available for treatment of acute bleeding 
in patients with congenital fibrinogen deficiency. Recent studies have shown that 
administration of human fibrinogen results in improved clot strength, as measured 
by thromboelastometry (TEM) (41), and human fibrinogen concentrate to be ef-
fective in reducing bleeding and the number of transfusions in surgical procedures 
(27, 42-44).  
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Coagulation factor XIII 
FXIII is a protransglutaminase present in plasma and in the cytoplasm of platelets, 
monocytes and macrophages (45). In plasma, almost all FXIII is bound to fibrino-
gen in an inactivated form, and comprises two potentially active subunits and two 
carrier subunits. The activation of FXIII occurs in the final phase of the coagula-
tion cascade by the action of thrombin and in the presence of Ca2+. The main 
function of FXIII is to cross-link fibrin into polymer structure. Fibrin cross-linking 
stabilises fibrin and makes it more resistant to shear stress and fibrinolysis. FXIII 
is essential for maintaining haemostasis, and severe deficiency leads to bleeding 
diathesis (46). 
FXIII is essential for haemostasis, but recent studies have also proved its im-
portance in wound healing and angiogenesis (46).  There are studies indicating 
that FXIII is required for maintaining pregnancy (45), and recent studies suggest 
that elevated FXIII level is a gender-specific risk factor of coronary artery disease 
and peripheral arterial disease in women (47). In cardiac surgery there is conflict-
ing evidence as to whether levels of FXIII are associated with increased bleeding 
after CPB or not. In a study on cardiopulmonary bypass patients, no association 
was found between FXIII activity and extent of postoperative bleeding (39). Re-
garding administration of FXIII, studies indicate supplementation of FXIII in 
patients with subnormal levels reduces postoperative blood loss and blood transfu-
sions after coronary surgery (48). In contrast, some recent studies do not show any 
effect of FXIII substitution on transfusion requirements or re-exploration in cardi-
ac surgery patients (49). 
 
Figure 3. Fibrin monomers polymerise to form fibres. The fibrin fibres 
form a meshwork stabilised by coagulation factor XIII. 
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Platelets 
Platelets play a crucial role in both normal haemostasis and pathological bleeding 
and thrombosis (50). Platelets are the smallest of the many cell types in the circu-
lation, averaging 2.0-5.0 µm in diameter, and have a life span of 7-10 days. Plate-
lets possess important secretory functions. They contain α-granules enclosing, for 
example, von Willebrand Factor (vWF) and FV, dense granules, and lysosomes 
(51). Platelet exocytosis releases molecules at sites of vascular injury to activate 
other cells or to facilitate cellular adhesion. During activation, granule proteins are 
expressed and adhesive proteins, coagulation factors and growth factors are re-
leased. Upon vascular damage, platelet attachment to subendothelial structures is 
dependent on vWF, fibronectin, and different types of collagen (52). Platelets 
contribute to the haemostatic process, through the formation of a haemostatic 
plug, and by being the procoagulant surface for plasma coagulation.  
Antiplatelet therapy is the cornerstone of treatment and prevention of ischemic 
events in patients with coronary artery disease. However, antiplatelet therapy is 
also associated with an increased risk of bleeding complications, especially in 
trauma and surgery. Newer antiplatelet drugs are more potent and produce more 
consistent inhibition of platelet aggregation via the P2Y12 ADP platelet receptor 
(53).  
Platelet function tests (PFT) may be used pre- and perioperatively to predict bleed-
ing and to monitor the efficacy of the various types of prohaemostatic therapies. In 
cardiac surgery, evidence indicates a reduction in blood transfusions when PFT is 
used (54). Recently developed point-of-care tests of platelet function have many 
advantages, including whole blood analyses, low sample volume, rapid availabil-
ity of the results bedside, and no requirement for a skilled technician. 
Platelet transfusions are commonly utilised during or after cardiac surgery with 
CPB (55). The effects of CPB on platelets include platelet activation due to expo-
sure to surfaces of the heart lung machine, platelet fragmentation, and impaired 
aggregation (12, 56, 57). There is convincing evidence that patients who have 
received antiplatelet therapy, such as aspirin, GPIIb/IIIa or P2Y12 receptor inhibi-
tors preoperatively, are at increased risk of bleeding (58-60).  
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Figure 4. Scanning electron microscopy of a coronary artery thrombus. 
Fibrin fibres are brown, platelet aggregates are grey, red blood cells are 
red and leukocytes are green. Image courtesy of John W. Weisel, PhD, 
Dept. of Cell & Developmental Biology, Perelman School of Medicine, 
University of Pennsylvania. 
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Blood transfusions 
In the beginning of the 17th century, the British physician William Harvey discov-
ered the blood circulation. The first successful blood transfusions between dogs 
and from sheep to humans were described in the end of the 17th century (61), but 
in most cases, transfusions from animals resulted in death and were outlawed by 
the Paris Society of Physicians in 1678. During the 19th century, attempts were 
made with transfusion of milk (62). Later, milk was replaced by saline due to 
adverse reactions to milk. 
 
                  
Figure 5. Richard Lower transfusing blood from lamb to man. Painting 
from 1692 by the German surgeon M G Purmann, held at Paris Faculty 
of Medicine. 
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The discovery of the AB0 blood group system by the Austrian physician Karl 
Landsteiner in the early 20th century made blood transfusions a therapeutic possi-
bility (63). In 1940 the Rh blood group system was discovered (64), and was soon 
known to be the cause of the majority of transfusion reactions. During and shortly 
after the Second World War, blood transfusions became routine treatment. 
In the 1970s, the Swedish professor Claes Högman developed a system for sepa-
rating and preserving the different blood components (65), and the use of whole 
blood was abandoned in most situations. 
 
 
Figure 6. The AB0 blood group system. 
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Risks with blood transfusions 
Transfusion of blood products saves lives and improves health, but unnecessary 
transfusions may expose patients to considerable risks and adverse effects. Blood 
transfusions are associated with a small, but not negligible risk of transmission of 
pathogens. Transfusion of blood products can result in immune response modula-
tion, with an increased risk of infections and malignancies (66-68). Data has been 
published suggesting transfusion with blood products as an independent risk factor 
for short- and long-term mortality after cardiac surgery (69-71). A recent study 
demonstrated that each unit of transfused red blood cells (RBC) in CABG patients 
was associated with increased morbidity and mortality (70). 
According to WHO, around 108 million blood donations are collected globally 
every year (72). In Sweden, about 500,000 units of blood are donated annually 
(73). Nevertheless, blood products are a scarce resource and unnecessary transfu-
sions reduce the availability of blood products for patients who are in need. The 
use of blood products is associated with considerable costs for society, and studies 
have shown that costs to society are markedly higher than institutional prices (74-
76). 
Blood conservation programmes 
Blood conservation programmes have been introduced successfully in a variety of 
specialties. In cardiac surgery there is compelling evidence that such programmes 
are effective in reducing postoperative transfusions (77-80). DeAnda et al. de-
scribed the implementation of a blood conservation programme in 2006, where the 
key component of success was believed to be the result of a multidisciplinary 
approach (80). Xydas et al. showed that a systematic implementation of a compre-
hensive blood conservation algorithm in cardiac surgery patients, led to significant 
reductions in the use of blood products (81). In 2013, LaPar et al. reported a suc-
cessful implementation, at state-wide level, of a multi-institutional blood conser-
vation programme in CABG patients (82).   
Transfusion guidelines 
The prevalence of perioperative transfusions in cardiac surgery varies widely, both 
between and within institutions (83, 84). The differences between institutions are 
probably due to differences in transfusion practice, guidelines and attitudes, as 
well as differences in patient characteristics. A multicentre European study re-
vealed that transfusion rates depend less on type of procedure, patient population 
or hospital, than on the individual physician (85). Trigger and target haemoglobin 
(Hb) thresholds for transfusions of red blood cells (RBC) are crucial for reducing 
the use of blood products. Studies of Jehovah’s Witnesses prove that moderate 
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anaemia of 80-100 g/L is not harmful if normovolemia is maintained (86, 87). 
There are still clinicians who transfuse patients to maintain a Hb level >100 g/L, 
despite the fact that a perioperative Hb level of 60 g/L may be tolerated as sug-
gested in the guidelines from the Society of Thoracic Surgeons and the Society of 
Cardiac Anaesthetists 2007 (78).  
Adherence to guidelines 
Even though the indications may be clear, the final decision on whether or not to 
transfuse a patient is made by the physician responsible. There is little information 
on which indication or combination of indications leads to transfusion in cardiac 
surgery patients, and on how often the decisions adhere to institutional guidelines. 
Low adherence to guidelines has been reported in orthopaedic patients (88), in 
patients with postpartum bleeding (89, 90), and in various kinds of intensive care 
patients (91). Adherence in cardiac surgery patients has been found to be high if a 
liberal transfusion regimen is used, but markedly lower if a more restrictive atti-
tude is adopted (92).  
Study objectives 
Massive bleeding after cardiac surgery is a serious complication associated with 
increased morbidity and mortality (10, 11). The bleeding is multifactorial and 
influenced by both surgical factors and an impaired haemostasis (12). Identifica-
tion of patients with increased risk for excessive bleeding and transfusion of blood 
products offer the possibility to take countermeasures. An inverse correlation was 
observed between plasma fibrinogen concentration and amount of postoperative 
bleeding in patients undergoing CABG in a small study from our group (38). In 
Paper I we designed a larger prospective non-interventional observational study 
on patients undergoing first-time elective isolated CABG. The relationship be-
tween preoperative fibrinogen plasma concentration and bleeding volume in the 
first 12 postoperative hours was investigated. 
Enhanced fibrinolysis, platelet dysfunction or loss, haemodilution and the surgical 
trauma are all factors that contribute to the impaired haemostasis in cardiac sur-
gery patients (12). Consumption of coagulation factors during CPB has also been 
suggested as contributing to coagulopathy after cardiac surgery (13, 93), but it is 
not evident whether all coagulation factors respond similarly to CPB and surgical 
trauma. In Paper II, the objective was to describe the activity of individual coagu-
lation factors in relation to haemodilution during and after cardiac surgery with 
CPB, and to investigate whether activity of any plasma coagulation factor corre-
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lated to bleeding after surgery. First-time elective CABG patients operated with 
CPB were enrolled in a prospective descriptive non-interventional study. 
Transfusion of blood products can be lifesaving, but, as mentioned earlier, there 
are considerable risks and adverse effects related with the usage of all blood prod-
ucts (66-68). Recent data suggests that transfusion of blood products is an inde-
pendent risk factor for both short- and long-term mortality after cardiac surgery 
(69-71, 94, 95). The decision to transfuse is based on multiple patient factors, but 
also on guidelines and attitudes. In 2009, 61% of the cardiac surgery patients in 
our institution were transfused with blood products. At that time there were no 
written transfusion guidelines. Because of this high transfusion prevalence, a 
blood conservation programme was initiated, with the intention to reduce transfu-
sions by 30%. In Paper III we evaluated the effects of this blood conservation 
programme on transfusion prevalence and volumes, cost of blood products, and 
potential effects on early complication rates. The effects were studied over a 24-
month period after the project was completed. 
A number of recent studies have shown that the implementation of more restric-
tive institutional guidelines for blood transfusions in cardiac surgery results in a 
reduced transfusion prevalence, an improved or unchanged clinical outcome, and 
reduced costs (77, 82, 96-98). In the light of these data we studied the prevalence 
of and indications for red blood cell transfusion in cardiac surgery patients, and 
assessed the adherence to our institutional transfusion guidelines (Paper IV). 
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Aims 
I. To investigate the relationship between preoperative levels of 
plasma fibrinogen, and postoperative bleeding and transfusions 
after CABG.  
 
II. To describe the activity of individual coagulation factors before and after 
CABG in relation to haemodilution and postoperative bleeding. 
 
II. To study the effects of a structured blood conservation pro-
gramme to reduce transfusions and transfusion-associated costs 
in cardiac surgery. 
 
IV. To describe prevalence and indications for red blood cell transfusion in 
cardiac surgery patients. 
 
V. To assess the adherence to local transfusion guidelines. 
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Patients and Methods 
Patients 
The Regional Research Ethics Committee approved all studies. In studies I and II, 
patients were included after written informed consent. The Ethics Committee 
waived the requirement for individual patient consent in studies III and IV. The 
studies were performed at the Department of Cardiothoracic Surgery, Sahlgrenska 
University Hospital, Gothenburg, Sweden.  
Paper I 
During 2005 and 2006, 175 patients undergoing primary elective isolated CABG 
with CPB were included in a prospective non-interventional observational study. 
Exclusion criteria were emergency CABG, known liver or kidney disease, and a 
surgical site of bleeding at re-exploration. Aspirin was not discontinued before 
surgery. The last dose of low molecular weight heparin (LMWH) was given the 
evening before surgery. Clopidogrel and Warfarin were discontinued at least 5 
days prior to surgery. Additional medication with, for example, naturopathic drugs 
and selective serotonin reuptake inhibitors (SSRI) were not taken into considera-
tion. Five patients were excluded due to re-exploration for surgical bleeding, leav-
ing 170 patients in the study (Table 1).  
Paper II 
Fifty-nine consecutive patients undergoing primary elective isolated CABG with 
CPB were initially included in a prospective descriptive non-interventional study. 
Patients with known bleeding disorders were excluded. Aspirin was not discontin-
ued before surgery. Clopidogrel was discontinued at least three days before sur-
gery. Two patients were excluded, one due to changed surgical approach and one 
due to ongoing treatment with clopidogrel, leaving 57 patients in the study (Table 
1). 
Paper III 
All adult patients undergoing cardiac surgery from February 2009 to January 2011 
at our institution were included in the study. The patients were divided into two 
groups. The first group comprised all patients undergoing surgery during the 12 
months prior to the blood conservation programme started (n=1128). The second 
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group comprised all patients undergoing surgery after the start of the programme 
(n=1034) (Table 1). 
Paper IV 
All 1034 patients in the second group in Paper III (n=1034) were included in the 
study. 
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Table 1. Patients characteristics in the four studies. Mean ± standard deviation, 
median and 25th and 75th percentiles or number (%) 
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Clinical management 
Paper I – IV 
Anaesthesia was induced with fentanyl and thiopentone followed by pancurioni-
um, and maintained with sevoflurane. During CPB, anaesthesia was maintained 
with propofol. Heparin was given (300 units/kg) to keep an activated clotting time 
(ACT) of more than 480 seconds. After CPB, heparin was reversed with prota-
mine to an ACT of less than 130 s. All patients received 2 g tranexamic acid at 
induction of anaesthesia and at the end of surgery. Aprotinin was not used in any 
of the patients.  
The CPB circuit included a membrane oxygenator and roller pumps. Non-pulsatile 
CPB technique with haemodilution was used. Cardioprotection was attained with 
cold blood cardioplegia. Weaning off CPB was performed after rewarming to a 
bladder temperature of 36°C. 
Study design and analyses 
Paper I 
The following pre- and perioperative variables were registered: age, gender, BMI, 
number of grafts, unstable angina, extracorporeal circulation time, aortic clamp 
time, and anticoagulation therapy. Hb concentration, PLT count, aPTT, PT, and 
fibrinogen were analysed the day before surgery. APTT was analysed with a rou-
tine assay (STA-R, STA-PTT Automat 5 reagent, Diagnostica Stago). PT was 
analysed with a prothrombin complex assay (STA-R, SPA 50 Reagent, Diagnosti-
ca Stago). Plasma fibrinogen concentration was measured by the modified method 
of Clauss (99), where excess thrombin is added to diluted, low-fibrinogen-
containing plasma, to determine the amount of clottable protein. 
Postoperative bleeding volume was defined as the total amount of chest tube 
drainage during the first 12 postoperative hours. Drainage volumes until re-
exploration for bleeding were recorded. Definition of a surgical bleeding was a 
specific bleeding controlled by surgical means. Transfusions of red blood cells, 
platelets, and plasma during the first 24 postoperative hours were recorded. Pre-
operative fibrinogen concentration was unknown for the treating physician.   
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Paper II 
The following pre- and perioperative variables were registered: age, gender, BMI, 
Euroscore, type of angina, preoperative medication, number of grafts, CPB-time 
and aortic clamp time. Plasma concentration of fibrinogen and plasma activity of 
coagulation factor II (FII), FV, FVII, FVIII, FIV, FX, FXI, and FXIII were ana-
lysed the day before surgery, 2 and 24 hours after surgery. At the same points Hb, 
HCT, and PT were analysed. Chest drainage during the first 12 postoperative 
hours was recorded. 
All samples were analysed at the coagulation laboratory at Sahlgrenska University 
Hospital. Fibrinogen was measured by the modified method of Clauss as in study 
I. Activity of FII (reference range 70-130%), FV (reference range 60-140%), FVII 
(reference range 50-160%), FVIII (reference range 50-200%), FIX (reference 
range 45-190%), FX (reference range 70-130%), and FXI (reference range 60-
140%) were determined using one stage clotting assay with specific factor defi-
cient plasma samples on the instrument STA-R (Diagnostica Stago, Asnieres, 
France). Activity of FXIII was measured using the Cobas Mira instrument (Roche, 
Basel, Switzerland) by a photometric method (reference range 70-140%). Coagu-
lation factor activity was reported as absolute values and values adjusted for hae-
modilution according to the formula: adjusted activity = absolute activity X (pre-
operative haematocrit / actual haematocrit) (99). Haemoglobin concentration, 
haematocrit and platelet count were analysed with clinical standard methods as in 
study I. 
Paper III 
The following variables were registered: preoperative: age, gender, BMI, additive 
Euroscore, antiplatelet therapy, preoperative Hb, aPTT, platelet count, serum 
creatinine and plasma fibrinogen concentration; peri- and postoperative: surgical 
procedure, CPB-time, aortic clamp time, acuteness, number of red blood cells, 
plasma and platelet transfusions during hospital stay, re-exploration for bleeding 
during the first 24 hours postoperatively, chest drain amounts during the first 12 
hours postoperatively or until re-exploration, length of stay in ICU, length of stay 
in hospital, ventilation time, mediastinitis, highest postoperative serum creatinine, 
haemoglobin levels day 4 after surgery. Data were compared between the two 
groups and in subpopulations on the basis of gender, age, surgical procedure and 
preoperative Hb level. The institutional price list for blood products from 2009 
was used to make cost calculations for both years (RBC concentrate: €102/unit; 
plasma: €35/unit; platelets: €290/unit). 
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The blood conservation programme consisted of three parts: 
1 Training. All staff involved in the care of the patients was given training 
about the risks and benefits of blood transfusions and the new transfusion 
guidelines in a 45-minute lesson. 
2. Guidelines. According to the new guidelines, indications for red blood cell 
transfusion should be based on clinical assessment of the patient´s haemo-
dynamic status, and/or signs of low oxygen delivery with mixed venous 
saturation below 55%. Absolute indications were Hb<60g/L, but in patients 
with ongoing significant bleeding an Hb level of >100 g/L was the target. 
Plasma was transfused in patients with ongoing bleeding (>200ml/h) and/or 
prolonged coagulation time in the absence of sustained heparin effect, indi-
cating coagulation factor deficiency. Platelets were transfused in patients 
with ongoing bleeding (>200ml/h) and/or low platelet count (<100x109/L) 
and/or suspected platelet dysfunction. The decision to transfuse or not was 
always at the discretion of the physician responsible. 
3. Transfusion log. In a transfusion log added to the patient records, all trans-
fusion episodes were recorded, together with time and type of transfusion, 
number of units, indication and patient status. Fig 7. 
Paper IV 
The transfusion log described in Paper III was used. When the indications for red 
blood cell transfusion were assessed, only transfusion episodes with red blood 
cells alone were included to avoid confusion as to whether the indication for trans-
fusion included plasma or platelets. Complete log records with red blood cells 
only were found in 351 transfusion episodes in 256 patients. Transfusion of red 
blood cells was considered to adhere to guidelines in patients with ongoing bleed-
ing, Hb <60g/L, signs of impaired oxygen delivery (SvO2 < 55%), heart failure, 
renal failure or cerebral deoxygenation indicated by INVOS (Somanetics INVOS 
Oxymeter, Covidien, Mansfield, MA, USA). The degree of adherence to guide-
lines, based on the transfusion log, was assessed by two observers (AJ and LT).  
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Figure 7. The transfusion log, in which indication for transfusion, type of 
blood product, patient status and laboratory variables were recorded. 
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Statistical analyses 
Paper I 
The relationship between haematological and demographic data and the volume of 
postoperative bleeding were analysed with simple linear regression. Multiple 
linear regression using forward selection was then used to identify factors inde-
pendently associated with bleeding volume. Groups were compared using two 
sample t-tests for continuous data and with chi-square tests for categorical data. 
Independent predictors for transfusion were analysed with multiple regression. 
Results are expressed as mean and standard deviation, or number and percentage. 
Statistical significance was defined as a p-value of < 0.05.  
Paper II 
All statistical analyses involving bleeding were performed with non-parametric 
tests. Intergroup comparisons were performed with the Mann-Whitney test, Krus-
kal-Wallis test or chi-square test. For correlation testing, Pearson´s test (normally 
distributed data) or Spearman rank sum test were used. Correlation between coag-
ulation factor activity and postoperative bleeding was performed on absolute ac-
tivities, without correction for haemodilution, and coagulation factor activity after 
surgery was compared to baseline with paired T-test. Results are expressed as 
mean and standard deviation, or number and percentage. Statistical significance 
was defined as a p-value of < 0.05. 
Paper III 
To compare normally distributed continuous variables, the independent sample t-
test was used, and to compare non-normally distributed continuous variables the 
Mann-Whitney U-test was used. Categorical variables were compared with a chi-
square test. The Kolmogorov-Smirnov test was used to test distribution of data. 
Results are expressed as mean and standard deviation and/or median and 25th and 
75th percentiles, or as number and percentage.  Statistical significance was defined 
as a p-value <0.05. 
Paper IV 
Univariable and multivariable predictors of red blood cell transfusion were calcu-
lated with logistic regression. The distribution of data was displayed with histo-
grams with normal curve and tested with Kolgomorov-Smirnov. Most continuous 
data were not normally distributed, so these were reported as median with 25th and 
75th percentiles. Data for pre- and perioperative fibrinogen levels was missing in 
4.3%, and in remaining variables data was missing in < 1.7%.  Statistical signifi-
cance was defined as a p-value < 0.05. 
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Results 
Paper I 
One of the 170 patients died of multiorgan failure 9 days after surgery. Four pa-
tients were re-explored for postoperative bleeding within 12 hours after surgery. 
Median postoperative bleeding was 360 mL/12 hours (range 110-2085 mL), and 
29 patients (17%) received blood transfusion during the first 24 postoperative 
hours. 
Mean preoperative fibrinogen plasma concentration was 4.2 ± 0.9 g/L (range 2.4-
8.1 g/L). One-hundred-and-sixteen (68%) patients had normal concentrations of 
plasma fibrinogen (2.0-4.5 g/L), while the remaining 54 patients (32%) had higher 
concentrations. Mean Hb concentration was 140 ± 14 g/L. PLT count, aPTT, and 
PT values were all within the normal range. 
Significant inverse correlations were found between postoperative bleeding and 
plasma fibrinogen concentration, PLT count, and Hb concentration. There were no 
correlations between bleeding and aPTT or between bleeding and PT. In multivar-
iate testing, preoperative fibrinogen concentration was the only factor inde-
pendently associated with postoperative bleeding (r=-0.53, p < 0.001). 
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Figure 8. Correlation between preoperative fibrinogen concentration and 
bleeding after CABG. There was a significant correlation between the two 
factors (r=-0.53, p < 0.001). 
Significant independent predictors of transfusion in a logistic regression model 
were preoperative fibrinogen concentration, female gender, and aortic clamp time. 
The absolute risk for transfusion of blood products in relation to gender and fi-
brinogen concentration is shown in Figure 9. 
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Figure 9. Absolute risk for transfusion of blood products during the first 
24 postoperative hours in men and women with different preoperative 
plasma concentrations of fibrinogen.  
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Paper II 
Coagulation factor activity was above the lower normal range in 56/57 patients, 
and a significant number of patients had coagulation factor activity over the upper 
normal range: 2 to 35 % for the individual coagulation factors. The unadjusted 
plasma factor activity was significantly reduced two hours after surgery in all 
factors, except for FIX. Twenty-four hours after surgery, unadjusted fibrinogen 
levels and FVIII activity increased compared to preoperatively, while FIX activity 
did not differ significantly. The activity of all other factors was reduced in com-
parison to preoperatively. 
In Fig 10, the changes from baseline activity after adjustment for haemodilution 
are shown. Mean plasma concentration of fibrinogen and activity of FII, FV, FX 
and FXII significantly decreased two hours after surgery, while activity of FVII 
and FXI did not differ, and activity of FVIII and FIX significantly increased. 
Twenty-four hours after surgery the plasma concentration for fibrinogen and activ-
ity of FVIII and FIX had increased significantly. Plasma activity of FV, FVII, FX, 
FXI, and FXIII decreased significantly, and activity of FII did not differ from 
baseline. 
 
Figure 10. Plasma concentrations of fibrinogen and plasma activity of 
FII, FV, FVII, FVIII, FIX, FX, FXI and FXIII before surgery and 2 and 
24 hours after surgery, in % of the preoperative value. 
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There were significant inverse correlations between postoperative bleeding vol-
ume and postoperative concentration of fibrinogen (r=-0.33, p=0.019) and pre- 
and postoperative activity of FXIII (r=-0.34, p=0.009 and r=-0.41, p=0.003, re-
spectively), but not with any of the other coagulation factors. 
Paper III 
The proportion of patients transfused with any blood product was 60.9% before 
the programme was started, and 48.3, 54.0, and 50.7%, 1-3 years after initiation.  
The first year after the programme was initiated, the proportion of patients trans-
fused with red blood cells decreased by 21.8%, plasma by 37.4%, and platelets by 
21% (Figure 12). Re-explorations for bleeding, early complication rate, and 30-
day mortality did not change after introduction of the programme (Table 2). The 
savings on blood products were €161,623 during the first 12 months after the 
programme was initiated (Table 3). 
  
Figure 11. Percentage of patients transfused with red blood cells, plasma, 
platelets and any blood product before and after initiation of the blood 
conservation programme.  *P <0.05, ***P <0.001. 
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Table 2. Outcome variables before and after the start of the blood conservation 
programme.  
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Table 3. Cost (in Euros) for blood products during a 12-month period after the 
start of the blood conservation programme.  
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Paper IV 
The prevalence of re-exploration for bleeding was 5.0% and median postoperative 
blood loss was 450 mL/12h. Thirty-day mortality was 2.6%. Of 1034 patients, 470 
(46%) were transfused with red blood cells. Twenty-five percent of the patients 
received red blood cells alone, and 21% received red blood cells in combination 
with plasma and/or platelets. The most common self-reported indication (69%) for 
transfusion of red blood cells alone was anaemia. Hypovolemia was reported in 
56%, heart failure in 19%, and ongoing bleeding in 7% of the cases (Figure 13). 
Mean haemoglobin level was 81 g/L before blood transfusion. Only 43% of the 
red blood cell transfusions were administered in accordance with institutional 
guidelines. 
 
Figure 12. Self- reported indications for transfusion with red blood cells 
only in 351 transfusion occasions in cardiac surgery patients.  
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Figure 13. Adherence to guidelines for red blood cell transfusion at dif-
ferent periods of time. 
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Discussion 
Plasma fibrinogen level, bleeding and transfusion 
Knowledge of fibrinogen and its role in bleeding and coagulation has increased 
steadily. In the early part of our studies, it was suggested that plasma fibrinogen 
levels of higher than 1.0 g/L were sufficient to ensure that the coagulation was not 
limited by the fibrinogen concentration (100), and guidelines recommended ad-
ministration of fibrinogen to maintain plasma fibrinogen levels <0.5-1.0 g/L (101). 
In Study I, mean plasma concentration of fibrinogen was 4.2 ± 0.9 g/L, and 32% 
of the 170 elective CABG patients had a preoperative fibrinogen concentration 
above the upper normal limit of 4.5 g/L. This is explained by the association be-
tween elevated levels of fibrinogen in ageing (32) and in cardiovascular risk (35, 
36). In Study I, the results indicate that a fibrinogen level of 1g/L is not sufficient 
for haemostasis when the coagulation system is defied by cardiac surgery, the use 
of CPB, and haemodilution. Our conclusion is that plasma fibrinogen concentra-
tion is a limiting factor for postoperative haemostasis, and that fibrinogen levels, 
even in the normal range, may be too low to ensure appropriate coagulation during 
and after major surgical procedures. This is confirmed in more recent studies in 
cardiac (102) and scoliosis (40, 102) surgery. Consistent with these findings, Eu-
ropean guidelines on the management of severe bleeding in the perioperative set-
ting and in trauma patients now recommend using fibrinogen concentrate if signif-
icant bleeding is accompanied by plasma concentrations <1.5-2.0 g/L (103, 104). 
Identifying patients at risk of excessive postoperative bleeding would offer the 
possibility to optimise perioperative management. If patients at increased risk for 
postoperative bleeding were identified, countermeasures could be initiated. Prior 
to cardiac surgery there is a widespread use of laboratory tests. Routine screening 
tests such as activated thromboplastin time (aPTT), prothrombin time (PT) and 
platelet count, have no or limited ability to identify patients with increased bleed-
ing risk (18-20). In study I we found no correlation between bleeding and aPTT 
and PT. However the correlation between plasma fibrinogen level and postopera-
tive bleeding volume was significant (r=-0.53). A significant, but less prominent 
correlation was also found between bleeding and PLT count (r=-0.26). Fibrinogen 
alone was independently associated with bleeding in the multivariate test. The 
results suggest that preoperative measurement of fibrinogen concentration in 
CABG patients provides additional information about bleeding and transfusions, 
and may be measured, particularly in patients with other risk factors of increased 
bleeding. Moreover, recent studies on fibrinogen levels in postoperative cardiac 
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surgery patients have shown a predicted risk of postoperative bleeding (105, 106). 
In study II, there was a significant correlation between fibrinogen, measured 2 
hours postoperatively, and postoperative bleeding. However, there was no correla-
tion between preoperative fibrinogen levels and postoperative bleeding, which 
may be explained by the small study population. The strong correlation between 
preoperative fibrinogen levels and postoperative bleeding suggests that the time-
point when fibrinogen is measured is of less importance. A meta-analysis from 
2014 on both pre- and postoperative fibrinogen levels showed a weak to moderate 
significant correlation between fibrinogen and bleeding in cardiac surgery (31).  
In study I, an association was shown between preoperative fibrinogen concentra-
tion and transfusion of red blood cells. These results could not be reproduced in a 
larger study from our group (102). One reason might be that, in study I, we only 
registered transfusions during the first 24 postoperative hours, whereas the study 
by Walden et al. (97) included all transfusions given during hospital stay. Indica-
tions for red blood cell transfusions are multifactorial, especially after the immedi-
ate postoperative period, as was also shown in Paper IV. 
Correlation between postoperative bleeding,            
and fibrinogen and coagulation factor XIII 
Of all the coagulation factors analysed in study II, only postoperative fibrinogen 
and pre- and postoperative FXIII were associated with postoperative blood loss. 
The association between FXIII activity and bleeding volume has been investigated 
in a few studies, with varying results.  In a study by Blome in 2005, a marked 
decrease in plasma activity of FXIII during CPB was not associated with postop-
erative bleeding (39). However, the results may not be comparable since the pa-
tients in their study were treated with aprotinin. Conversely, there are studies 
pointing to the importance of FXIII levels for maintaining clot strength and reduc-
ing postoperative blood loss (107), and studies suggesting replacement therapy 
with FXIII to be considered in postoperative bleeding (48). However, conflicting 
results have been published recently (49).  
Together with the activity measurements, our results indicate that coagulation 
factors involved in the first steps of the coagulation cascade (before thrombin 
generation) do not reach critically low levels after CABG with limited bleeding 
and limited operation time. In contrast, two factors involved in the end of the 
coagulation cascade, fibrinogen and FXIII, correlated to postoperative blood loss. 
This indicates that clot stability may be more critical than clot initiation for hae-
mostasis after uncomplicated cardiac surgery. This speculation is supported in a 
study by Solomon et al., where fibrin formation was more impaired than thrombin 
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generation and platelet function immediately after CPB (108). Furthermore, in a 
study on paediatric surgery patients, where transfusions were guided by intraoper-
ative thromboelastometry (TEM), the results demonstrated that clot formation was 
the main limiting factor for postoperative haemostasis and that the use of TEM led 
to a marked reduction in plasma transfusions, while transfusions of fibrinogen and 
platelets increased (109). This supports the theory that impaired coagulation after 
cardiac surgery with CPB, most probably is a consequence of impaired clot stabil-
ity rather than compromised clot initiation. Additional studies support the fact that 
fibrinogen and FXIII are crucial for the quality of the clot (110-112). 
The effects of a blood conservation programme 
Transfusions of blood products can be lifesaving but are associated with consider-
able risks (66-68). In cardiac surgery, transfusions have been associated with in-
creased mortality (69-71). In 2009, 61% of the patients undergoing cardiac sur-
gery at our institution were transfused with blood products. This high prevalence 
initiated a blood conservation programme, to reduce transfusions and transfusion-
related costs, where a more restrictive approach to transfusion than before was 
advocated. In Paper III the effects of the programme were studied. The results 
demonstrated that a structured blood conservation programme reduces transfusion 
prevalence and costs for blood products, and that the reduction prevalence was 
maintained for at least 3 years. This was achieved without compromising patient 
safety. 
The difference in patient mix between the years suggests that there in fact may 
have been an increased need for blood transfusions during the year the programme 
was introduced. Preoperative levels of fibrinogen were significantly lower and, in 
addition, the proportion of patients undergoing acute surgery was higher, though 
not significantly, during the programme year. Both factors have been shown to 
correlate with increased postoperative bleeding and transfusions after cardiac 
surgery (66, 77, 102). Despite this, the proportion of patients who received RBC 
was reduced by 22%, plasma by 37% and platelets by 21%. The proportion of 
patients who received any type of blood transfusion was reduced by 21%. 
Prior to the introduction of the blood conservation programme, three simple steps 
were taken. The clinic's guidelines for blood transfusions were revised, all staff 
with patient contact underwent a 45-minute lesson on the benefits and risks of 
blood transfusions, and the clinic's new guidelines were reviewed. All patients 
received a transfusion log, where status, indication, and type of blood transfusion 
were recorded. With these very simple, neither time-consuming nor costly 
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measures, the utilisation of blood products could be reduced by 21% and the total 
saving for blood products was €161,623. 
As mentioned earlier, there are studies indicating increased mortality in cardiac 
surgery patients after transfusion of as little as 1-2 units of red blood cells (69, 70). 
A study by Paone et al. showed that 1-2 units were administered to 26% of the 
total population, corresponding to 50% of all patients receiving blood transfusions 
(70). In most cases, transfusions at this level are probably redundant. In our mate-
rial 37% of the patients were transfused with 1-2 units of red blood cells before 
the programme was initiated. Before the introduction of the programme, we be-
lieved that transfusions of 1-2 units would be significantly reduced and that the 
greatest savings of blood products would come from this subgroup of patients. 
Surprisingly, there was no decrease at all in this group (37% vs. 41%), although 
the overall transfusion prevalence decreased. This suggests there is room for fur-
ther reduction in transfusion prevalence than that was achieved with the pro-
gramme. 
After the introduction of the programme, almost 1,600 units of blood products 
were saved during a 12-month period. These blood products could be used for 
patients who were in greater need of them. The financial savings were substantial 
(Table 3) although the net saving was slightly lower as the reduced use of plasma 
resulted in an increase in the use of albumin and other plasma expanders. On the 
other hand, previous studies have shown that the cost of blood products for society 
is significantly higher than institutional prices (74-76). 
Adherence to transfusion guidelines 
In Paper IV the prevalence and timing, as well as the indications for and predic-
tors of red blood cell transfusion in cardiac surgery patients, were studied. Adher-
ence to guidelines was also analysed. Transfusion of red blood cells was consid-
ered to adhere to guidelines when given to patients with Hb <60 g/L, signs of 
impaired oxygen delivery (SvO2 < 55%), ongoing bleeding, heart failure, renal 
failure or cerebral deoxygenation indicated by INVOS. A haemoglobin level of 
<60 g/L might be considered low, but in our institutional guidelines we tried to 
avoid transfusion of red blood cells based only on haemoglobin levels, and instead 
base the decision to transfuse on clinically significant anaemia. Our transfusion 
policy was based on the recommendations of the Society of Thoracic Surgeons 
and the Society of Cardiovascular Anesthesiologists (66).  
In our study, only 43% of RBC transfusion episodes adhered to institutional 
guidelines. Similar rates have been reported in intensive care unit patients, in 
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patients with postpartum bleeding, and in orthopaedic patients (88, 90, 91). In 
cardiac surgery patients, a high adherence to guidelines (84%) was seen when a 
liberal transfusion policy was used (Hb <95 g/L). The adherence was markedly 
lower (41%) with a more restrictive policy (Hb <70 g/L during and <75 g/L after 
surgery) (92). This last study is not directly comparable since different transfusion 
triggers and definitions of adherences were used. However, the results were sur-
prisingly similar (43% vs. 41% adherence). 
This is the first study to report the prescriber´s indication for red blood cell trans-
fusion in cardiac surgery. In this patient group, the most common indication for 
red blood cell transfusion was anaemia, followed by hypovolemia. The anaemia 
was an expected finding, but the fact that RBC was prescribed for hypovolemia 
was a surprise. However hypovolemia alone was rarely an indication for RBC 
transfusions; instead a combination of hypovolemia and another indication was 
common. One explanation is that patients with a clinical requirement for volume 
substitution and medium to low haemoglobin levels were prescribed RBC transfu-
sions, with an intention to solve both problems. Ongoing bleeding was a rare indi-
cation for transfusing only red blood cells. However, during ongoing bleeding, 
transfusion of RBC and plasma and/or platelets is often prescribed. In our material 
this was the case in approximately 20% of the operated patients during the study 
period. 
Limitations 
There are important limitations in studies I and II. The studies are single-centre 
experiences. Transfusion thresholds, haematological practice, use of thromboelas-
tography, discontinuation of anticoagulants, and the use of perioperative antifibri-
nolytics may not be applicable to other centres. However, all patients were treated 
with tranexamic acid and this may well reflect the real world, since tranexamic 
acid today is used in the vast majority of cardiac surgery patients in Sweden and 
probably also in centres worldwide. Furthermore, there are numerous factors be-
yond coagulation status influencing postoperative bleeding volume, so bleeding 
volume is not an optimal endpoint. However transfusion requirement, another 
possible endpoint, is also multifactorial, possibly even more so.    
In study III, factors not related to the transfusion policy may have changed during 
the study period. Non-adherence to transfusion guidelines may also have influ-
enced the results, but this issue was addressed in study IV.  
In Paper III, higher-quality data for the second period may have introduced bias 
since these data were collected prospectively, while data for the period before the 
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start of the project were retrieved from prospective registers. However, prospec-
tive collection during the first period would also have biased the results since all 
staff would have been aware of the upcoming changes. This could have influenced 
decision-making regarding blood transfusions.  
The fact that Paper IV is a single-centre study raises the question of whether the 
experience can be applied to other institutions. The patients had the same risk 
factors for transfusions as previously reported, indicating the results could be 
relevant to other institutions. Since the transfusion log did not allow us to distin-
guish between indications for red blood cells, plasma and platelets, indications for 
transfusions were analysed in patients receiving only red blood cells, which could 
be considered a limitation.  
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Conclusions 
I. Pre- and postoperative fibrinogen concentration and factor XIII activity 
correlates to postoperative bleeding volume after CABG, and may be 
used to identify patients with increased risk of bleeding (Papers I & II). 
 
II. There is a marked disparity of clotting factor activity after cardiac sur-
gery with CPB (Paper II).  
 
III. The introduction of a structured blood conservation programme in cardi-
ac surgery is safe, and reduces the use and costs of blood products (Paper 
III). 
 
IV. Transfusions of red blood cells are given to cardiac surgery patients not 
only because of anaemia, but also because of other indications (Paper 
IV). 
 
V. The adherence to transfusion guidelines among treating physicians is low 
(Paper IV).    
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